Dianthus Therapeutics
DNTH
76 hedge funds and large institutions have $782M invested in Dianthus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 2 closing their positions.
2,273% more capital inflows, than outflows
Capital inflows: $362M | Capital outflows: $15.3M
1,850% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 2
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
200% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 8
95% more funds holding
Funds holding: 39 → 76 (+37)
19.41% more ownership
Funds ownership: 69.44% → 88.85% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$65M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
+$50.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$32.6M |
| 5 |
VA
VR Adviser
New York
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.21M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$5M |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.42M |
| 4 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$1.09M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$302K |
DNTH Hedge Fund Activity: Q1 2024 in Review
76 of the 6,963 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2024, worth a combined $782M — up 634% from $107M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new DNTH positions and 2 closed out — a net gain of 37 holders — while 24 added to existing stakes and 8 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $65M. The largest seller was Tang Capital Management, cutting an estimated $5.21M.
- 76 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2024, up from 39 in Q4 2023.
- Funds reported $782M of Dianthus Therapeutics stock for Q1 2024, up 634% quarter-over-quarter.
- 39 funds opened new Dianthus Therapeutics positions in Q1 2024 and 2 closed out, a net change of +37 holders.
- The largest Dianthus Therapeutics buyer in Q1 2024 was Bain Capital Life Sciences Investors, an estimated $65M added.
- The largest Dianthus Therapeutics seller in Q1 2024 was Tang Capital Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q1 2024.